RE: Addictions Market1 Dec 2024 20:09
July rns
Prof David Nutt, CSO Awakn Life Sciences Corp, commented:
"This Collaboration is a significant step forward for our new chemical entity programme. Graft Polymer's expertise in drug delivery systems will be invaluable as we advance our research.
"We are confident that this partnership will accelerate the development of new therapeutic options for addiction and mental health, areas in desperate need of innovative solutions